Wnt/β-catenin-pathway as a molecular target for future anti-cancer therapeutics

被引：168
作者：
Dihlmann, S [1 ]
Doeberitz, MVK [1 ]
机构：
[1] Heidelberg Univ, Inst Mol Pathol, D-69120 Heidelberg, Germany
来源：
INTERNATIONAL JOURNAL OF CANCER | 2005年 / 113卷 / 04期
关键词：
signaling; targeted therapy; pharmacologic inhibitor; NSAID; endostatin; proteasomal degradation; oncolytic virus;
D O I：
10.1002/ijc.20609
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Conventional chemotherapeutic drugs used for the treatment of cancer patients in advanced stages have yielded only limited benefit, regarding survival time not to mention cure of the patients. To improve the clinical outcome of cancer, agents aimed at novel molecular targets are required. Colorectal and many other cancers are caused by hyperactivity of the Wnt/beta-catenin signaling pathway that results in constitutive beta-catenin mediated transactivation of T cell factor (Tcf)-dependent genes. Accordingly, disruption of this signaling pathway holds promise for the development of new anti-cancer drugs. Our study describes recent therapeutic strategies to interfere with tumor growth by blocking the unrestricted activation of the Wnt/beta-catenin pathway. The antagonists, which may become lead compounds of new anticancer therapeutics include established drugs in new application areas, recombinant biomolecules, virus mediated selective cell killing, and small molecules, disrupting protein-protein interactions.
引用
收藏
页码：515 / 524
页数：10
相关论文
共 120 条
[1]   beta-catenin is a target for the ubiquitin-proteasome pathway [J].
Aberle, H ;
Bauer, A ;
Stappert, J ;
Kispert, A ;
Kemler, R .
EMBO JOURNAL, 1997, 16 (13) :3797-3804
[2]   A randomized trial of aspirin to prevent colorectal adenomas [J].
Baron, JA ;
Cole, BF ;
Sandler, RS ;
Haile, RW ;
Ahnen, D ;
Bresalier, R ;
McKeown-Eyssen, G ;
Summers, RW ;
Rothstein, R ;
Burke, CA ;
Snover, DC ;
Church, TR ;
Allen, JI ;
Beach, M ;
Beck, GJ ;
Bond, JH ;
Byers, T ;
Greenberg, ER ;
Mandel, JS ;
Marcon, N ;
Mott, LA ;
Pearson, L ;
Saibil, F ;
van Stolk, RU .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (10) :891-899
[3]   Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance [J].
Boehm, T ;
Folkman, J ;
Browder, T ;
OReilly, MS .
NATURE, 1997, 390 (6658) :404-407
[4]   Sulindac targets nuclear β-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines [J].
Boon, EMJ ;
Keller, JJ ;
Wormhoudt, TAM ;
Giardiello, FM ;
Offerhaus, GJA ;
van der Neut, R ;
Pals, ST .
BRITISH JOURNAL OF CANCER, 2004, 90 (01) :224-229
[5]   Non-steroidal anti-inflammatory drugs with activity against either cyclooxygenase 1 or cyclooxygenase 2 inhibit colorectal cancer in a DMH rodent model by inducing apoptosis and inhibiting cell proliferation [J].
Brown, WA ;
Skinner, SA ;
Malcontenti-Wilson, C ;
Vogiagis, D ;
O'Brien, PE .
GUT, 2001, 48 (05) :660-666
[6]   Inhibition of β-catenin translocation in rodent colorectal tumors -: A novel explanation for the protective effect of nonsteroidal antiinflammatory drugs in colorectal cancer [J].
Brown, WA ;
Skinner, SA ;
Vogiagis, D ;
O'Brien, PE .
DIGESTIVE DISEASES AND SCIENCES, 2001, 46 (11) :2314-2321
[7]   Replicating adenoviruses that target tumors with constitutive activation of the wnt signaling pathway [J].
Brunori, M ;
Malerba, M ;
Kashiwazaki, H ;
Iggo, R .
JOURNAL OF VIROLOGY, 2001, 75 (06) :2857-2865
[8]  
Chan CW, 1999, ALZHEIMERS REP, V2, P113
[9]   Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis [J].
Chan, TA ;
Morin, PJ ;
Vogelstein, B ;
Kinzler, KW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (02) :681-686
[10]   Targeted inactivation of CTNNB1 reveals unexpected effects of β-catenin mutation [J].
Chan, TA ;
Wang, ZH ;
Dang, LH ;
Vogelstein, B ;
Kinzler, KW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (12) :8265-8270
12345678910